Anuh Pharma share price today

Anuh Pharma Ltd's share price was ₹82.86 at the close on 4 November 2026. It has been rising for 7 weeks. That is 0.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹70 and ₹95, and at that close it sat 52% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Anuh Pharma Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 12 weeks in a row.

Over the last 11 years the share price moved +74% while the NIFTY 500 moved +243%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

One change stood out: operating margin up 3 points on a year earlier.

1. Operating margin up 3 points on a year earlier

   9% in the September 2026 quarter, from 6%.

For July to September 2026 (the quarter ended 30 September 2026), Anuh Pharma reported revenue of ₹185 crore, down 0.5% from ₹186 crore a year earlier, and a profit of ₹11.0 crore, up 37.5% from ₹8.00 crore.

Anuh Pharma results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Anuh Pharma closed at ₹82.86 on 4 November 2026, down 3.6% from ₹85.99 a year earlier (7 November 2025) and up 54.9% over five years. Its highest weekly close since April 2016 was ₹127.78 on 26 April 2024.

Anuh Pharma share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

560 weekly closes from 1 April 2016 to 4 November 2026.

4 Nov 2026: Anuh Pharma closed at ₹82.86, down 4.9% on the week and down 4.6% on the month. Results for July to September 2026: Revenue down 0.5% and profit up 37.5% on a year earlier.

Earlier

• 5 Aug 2026: ex-date for a dividend of ₹1.50 a share.
• 15 Jul 2025: Bonus issue: 1 new share for every 1 held (ex-date).

Anuh Pharma paid ₹1.50 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 1.81% at the ₹82.86 close on 4 November 2026. The last was a dividend of ₹1.50 a share, ex-date 5 August 2026.

Anuh Pharma dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Anuh Pharma Ltd paid out 37% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

Anuh Pharma is on 4 of our India lists: Momentum stocks, Dividend stocks, Penny stocks and Pharma stocks.

Anuh Pharma Ltd earned ₹11.0 Cr of net profit in the Sep 2026 quarter, +37.5% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹41.0 Cr. Over 10 years profit has grown 4.7% a year on average. That is 5.9% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹8.0 Cr.

For the full year, FY26 profit was ₹41.0 Cr (−12.8% on the year before).

Why profit moved: revenue changed −0.5% on a year earlier and the margin moved +3.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +26.3% and revenue +7.2%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Anuh Pharma Ltd reported ₹185 Cr of revenue in the Sep 2026 quarter, −0.5% on the same quarter a year earlier. Over 10 years it has grown 9.0% a year on average. The last full year, FY26, came in at ₹772 Cr. The last four reported quarters add to ₹778 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹772 Cr, +16.6% on the year before.

Recent pace: the last four quarters grew +7.2% on average, against 9.0% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +6.6%, against +10.3% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +23.7%, against −10.7% a year (accelerating).

Anuh Pharma Ltd's operating margin was 9.0% in the Sep 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 8.0% and 12.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +2.8 percentage points on the year while gross margin changed +3.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 32% of Anuh Pharma Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 its operations used ₹3.0 Cr of cash, against ₹41.0 Cr of profit. After ₹10.0 Cr of spending on assets, free cash was −₹13.0 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 32% of profit came in as cash: the cash cycle got 41 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 41 days longer. The next section looks at where the cash is stuck.

Anuh Pharma Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 89 days in FY26, up from 48 days in FY21. It spent ₹33.0 Cr on assets over the last 3 years. Customers take 113 days to pay, and stock sits for 90 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹772 Cr, each day of that cycle ties up about ₹2.1 Cr, so roughly ₹188 Cr is tied up in the business at any time.

FY26: customers took 113 days to pay and stock sat for 90 days, about 3.0 months of sales sitting as stock, for a full cycle of 89 days, longer than FY21's 48.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 90 days. Customers pay about 113 days after that. Suppliers are paid at 114 days. Together that makes the 89-day cycle.

Spending on assets: ₹33.0 Cr over the last 3 years, against ₹29.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Anuh Pharma Ltd's P/E is 17.4×, near the low end of its own history: it has been lower only 29% of the time. Its usual P/E (the middle reading) is 19.7×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.